Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

NCT04425629 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10078

Enrollment

INDUSTRY

Sponsor class

Stopped Emerging SARS-CoV-2 variants impacting susceptibility to study drug

Conditions

COVID-19

Interventions

DRUG: casirivimab+imdevimab combination therapy

Sponsor

Regeneron Pharmaceuticals